Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.49 |
| ▸ | HPN | P05981 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
| ▸ | HMGCR | P04035 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13847954 | 0.85 | VCAM1 (0.72) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8212308 | 0.82 | VCAM1 (0.80) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL6054982 | 0.81 | VCAM1 (0.92) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042606 | 0.80 | VCAM1 (0.81) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8213444 | 0.79 | VCAM1 (0.78) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042604 | 0.78 | VCAM1 (0.81) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8191857 | 0.78 | VCAM1 (0.79) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL13847955 | 0.77 | VCAM1 (0.60) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12012989 | 0.77 | VCAM1 (0.83) | VCAM1ALOX15HPNMAPTSIRT5 | |
| Succinobucol SCHEMBL347492 | 0.77 | VCAM1 (1.00) | VCAM1ALOX15HPNMAPTSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | VCAM1 3502/4885ALOX15 1530/4885HPN 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.